 "Dr Reddys Labs gains 7% as profit grows 30% YoY in Q2, margins expand")
Shares of Dr Reddy's Laboratories moved higher by 7 per cent to Rs 4,877 on the BSE in Friday's intra-day trade after the company reported 30 per cent year-on-year (YoY) growth in profit after tax (PAT) at Rs 992 crore in September quarter (Q2FY22), aided by healthy revenue growth. The pharmaceutical company had reported a profit of Rs 762 crore in the year-ago quarter.
At 02:12 pm, the stock was trading 5 per cent higher at Rs 4,820, as compared to a 1.3 per cent decline in the S&P BSE Sensex. It had hit a 52-week high of Rs 5,614 on July 7, 2021.
In Q2FY22, Dr Reddy's revenues grew 18 per cent YoY at Rs 5,763 crore from Rs 4,897 crore in the previous year quarter. Earnings before interest, tax, depreciation and amortization (ebitda) rose 23 per cent YoY at Rs 156 crore while margins improved 110 basis points (bps) to 27 per cent from 25.9 per cent in Q2FY21.
However, the company's gross profit margins decreased by 50 bps at 53.4 per cent over previous year, majorly on account of price erosion and lower export benefits, partially offset by leverage benefit on manufacturing overheads.
"Dr Reddy's global generic business grew 19 per cent YoY to Rs 4,743 crore driven by Covid portfolio, new product launches and base business volume traction across key markets. However, this was offset partly by price erosion in some of our products," the company said.
Sequentially, gross profit margins increased by 120 bps, driven majorly by leverage benefit on manufacturing overheads partially offset by price erosion, it said.
At 02:12 pm, the stock was trading 5 per cent higher at Rs 4,820, as compared to a 1.3 per cent decline in the S&P BSE Sensex. It had hit a 52-week high of Rs 5,614 on July 7, 2021.
In Q2FY22, Dr Reddy's revenues grew 18 per cent YoY at Rs 5,763 crore from Rs 4,897 crore in the previous year quarter. Earnings before interest, tax, depreciation and amortization (ebitda) rose 23 per cent YoY at Rs 156 crore while margins improved 110 basis points (bps) to 27 per cent from 25.9 per cent in Q2FY21.
However, the company's gross profit margins decreased by 50 bps at 53.4 per cent over previous year, majorly on account of price erosion and lower export benefits, partially offset by leverage benefit on manufacturing overheads.
"Dr Reddy's global generic business grew 19 per cent YoY to Rs 4,743 crore driven by Covid portfolio, new product launches and base business volume traction across key markets. However, this was offset partly by price erosion in some of our products," the company said.
Sequentially, gross profit margins increased by 120 bps, driven majorly by leverage benefit on manufacturing overheads partially offset by price erosion, it said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%